MedTrace Logo

Improve Management of Heart Failure With Procalcitonin

NCT02392689 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 759

Last updated 2018-07-23

No results posted yet for this study

Summary

Patients presenting to the Emergency Department with shortness of breath and (suspected) heart failure will be screened and randomized to either a standard of care or a procalcitonin-guided arm.

Procalcitonin-guided arm: a procalcitonin level (cutoff 0.2 ng/ml) will be used to support decision on antibiotic therapy initiation.

Standard of care arm: the decision on antibiotic therapy will be based on the physicians intent to treat.

The patients will be followed up 30 and 90 days after randomization to evaluate the survival status, re-hospitalizations and further antibiotic therapies.

Conditions

Interventions

OTHER

Procalcitonin

Procalcitonin guided antibiotic therapy

Sponsors & Collaborators

  • Brahms AG

    lead INDUSTRY

Principal Investigators

  • Alan Maisel, MD · University of California-San Diego/VA San Diego Healthcare System

  • Martin Möckel, MD · university hospital Charitè Berlin

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-04-05
Completion
2018-04-14

Countries

  • Denmark
  • Germany
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02392689 on ClinicalTrials.gov